Disease: Obesity ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0028754
Disease: Obesity
Obesity 		0.060 Biomarker disease BEFREE Newer GLP-1RAs, such as semaglutide, or other drugs in development for obesity may have advantages over liraglutide. 31790314 2020
CUI: C0028754
Disease: Obesity
Obesity 		0.060 Biomarker disease BEFREE The meta-analyses of patient subgroups showed a significant reduction in MACE with GLP-1RAs, irrespective of gender, advanced age and obesity. 31595657 2020
CUI: C0028754
Disease: Obesity
Obesity 		0.060 Biomarker disease BEFREE A number of GLP-1 receptor agonists (GLP-1RAs) are currently used in treatment of type 2 diabetes and obesity. 28722834 2018
CUI: C0028754
Disease: Obesity
Obesity 		0.060 Biomarker disease BEFREE Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are approved for the treatment of type 2 diabetes and obesity. 30459715 2018
CUI: C0028754
Disease: Obesity
Obesity 		0.060 Biomarker disease BEFREE Recently, GLP-1RAs have been approved for the treatment of obesity to reduce body weight in non-diabetic patients. 28822994 2017
CUI: C0028754
Disease: Obesity
Obesity 		0.060 Biomarker disease BEFREE Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are registered for treatment of both obesity and type 2 diabetes. 27717222 2017